BioSpace News Archive

Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol ® Cyclo™ for treatment of Niemann-Pick Disease Type C

University Medical Center New Orleans, a part of LCMC Health, and Humana Inc., a leading health and well-being company, have signed an in-network agreement, expanding access to care for Humana Medicare members.

Venatorx Pharmaceuticals today announced that it has two data presentations at IDWeek 2020, which is taking place virtually, starting today through October 25, 2020. The details of the presentations are as follows: Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-Beta-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in

Award recognizes the contributions made by the nation’s most promising oncology professionals under the age of 40

Precision Genetics, a leading healthcare technology company and high capacity molecular testing lab, has added saliva collection to their existing portfolio of validated Covid-19 testing options submitted under Emergency Use Authorization (EUA) by the Food and Drug Administration. Precision Genetics sur

Mycovia Pharmaceuticals, Inc. (“Mycovia”) , an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced that the last patient has completed their final visit in Mycovia’s Phase 3 pivotal clinical trials of oteseconazole (VT-1161) in patients with recurrent vulvovaginal

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2020 results before the market opens on Wednesday, November 4, 2020, to be followed by a conference call at 8:30 a.m. (Eastern Time) You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (internationa

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Xerox Holdings Corporation (NYSE: XRX) has published its 2020 Global Corporate Social Responsibility Report detailing data, accomplishments and goals relating to its work regarding the environment, society and governance.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present at the following investor conferences next month: